DanielHAhnDOM.S.

Oncology • Scottsdale, AZ

Gastrointestinal Cancer, Hematologic Oncology

Senior Associate Consultant, Assistant Professor

Join to view full profile

Dr. Ahn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ahn's full profile

Already have an account?

Office
13400 E Shea Blvd
Scottsdale, AZ 85259
Phone+1 480-301-8000

Education & Training

Ohio State UniversityM.S., Clinical Investigation, 2014 - 2016
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2013 - 2016
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2009 - 2011
Texas College of Osteopathic MedicineClass of 2008

Certifications & Licensure

AZ State License 2016 - 2027
TX State License 2011 - 2026
OH State License 2013 - 2017
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

ASCO GI Symposium Merit Award ASCO, 2016
ASCO/CCF Young Investigator Award ASCO, 2015

Clinical Trials

TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2017 Dec 11
Completed
Phase 1
A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma Start of enrollment: 2018 Mar 07
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
Active, not recruiting
Phase 3
Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Start of enrollment: 2019 Apr 16
Completed
Phase 1
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations Start of enrollment: 2020 Jun 24
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Minimal residual disease monitoring via ctDNA: a case report of Lynch syndrome with synchronous colorectal cancer and review of literature.
Cody Eslinger, Christina Wu, Daniel H Ahn
Journal of Gastrointestinal Oncology. 2024-06-30
6 citations
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study.
Daniel H Ahn, Afsaneh Barzi, Maya Ridinger, Errin Samuëlsz, Ramanand A Subramanian
Clinical Cancer Research. 2024-05-15
Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma.
Aakash Desai, Alexander H Xiao, Daheui Choi, Merih D Toruner, Daniel Walden
Cancers. 2024-05-13

Journal Articles

Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma
Mohamad Bassam Sonbol, Amit Mahipal, Zhaohui Jin, Kabir Mody, Mitesh J Borad, Daniel H Ahn, Tanios Bekaii-Saab, JAMA Oncology
Targeting the Stroma in Pancreatic Cancer
Daniel H Ahn, Ramesh K Ramanathan, Annals of Palliative Medicine

Press Mentions

Neoadjuvant Chemotherapy Regimen Extends Survival in Pancreatic CancerJuly 14th, 2022
Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic CancerJune 8th, 2021
Why Cardiff Oncology Stock Is Crashing TodayJanuary 15th, 2021
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Medical Association - AMA
Member
American Association for Cancer Research - AACR
Member